Abstract
People with advanced age experience greater morbidity and mortality from infectious diseases, due, in part, to immunosenescence.
Older and vaccinated individuals present with attenuated symptoms and signs in many infections.
When infection still occurs, vaccination remains cost effective to prevent infectious diseases or attenuate morbidity and mortality.
Vaccination rates >80% reduce spread, morbidity, and mortality of some infections through herd immunity.
Influenza, pneumococcal, tetanus/diphtheria, and herpes-zoster vaccinations are recommended for elders.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsReferences
References
Castle, S.C., Uyemura, K., Fulop, T., Makinodan, T. (2007). Host resistance and immune responses in advanced age. Clinics in Geriatric Medicine, 23(3), 463–479.
Aspinall, R., Del Giudice, G., Effros, R.B., Grubeck-Loebenstein, B., Sambhara, S. (2007). Challenges for vaccination in the elderly. Immune Ageing, 7, 4–9.
Stoll, G., Bendszus, M. (2006). Inflammation and atherosclerosis: novel insights into plaque formation and destabilization. Stroke, 37(7), 1923–1932.
Solenski, N.J. (2007). Emerging risk factors for cerebrovascular disease. Current Drug Targets, 8(7), 802–816.
Grau, A.J., Marquardt, L., Lichy, C. (2006). The effect of infections and vaccinations on stroke risk. Expert Review in Neurotherapy, 6(2), 175–183.
Lichy, C., Grau, A.J. (2006). Investigating the association between influenza vaccination and reduced stroke risk. Expert Review Vaccines, 5(4), 535–540.
Armstrong, E.P. (2007). Economic benefits and costs associated with target vaccinations. Journal of Managed Care Pharmacy, 13(7 Suppl. B), S12–S15.
Drummond, M., Chevat, C., Lothgren, M. (2007). Do we fully understand the economic value of vaccines? Vaccine, 25(32), 5945–5957.
Zimmerman, R.K., Middleton, D.B., Burns, I.T., Clover, R.D., Kimmel, S.R. (2007). Routine vaccines across the life span, 2007. Journal of Family Practice, 56 (Suppl. Vaccines), S18–S37, C1–3.
Sand, K.L., Lynn, J., Bardenheier, B., Seow, H., Nace, D.A. (2007). Increasing influenza immunization for long-term care facility staff using quality improvement. Journal of the American Geriatrics Society, 55(11), 1741–1747.
Zielinski, A. (2007). Tetanus in 2005. Przegl Epidemiology, 61(2), 287–289.
Fiscella, K., Dressler, R., Meldrum, S., Holt, K. (2007). Impact of influenza vaccination disparities on elderly mortality in the United States. Preventive Medicine, 45(1), 83–87.
Belshe, R.B. (2007). The burden of influenza and strategies for prevention. Managed Care, 16(Supp. 8), 2–6; 17–19.
Nichol, K.L., Nordin, J., Mullooly, J., Lask, R., Fillbrandt, K., Iwane, M. (2003). Influenza vaccination and reduction in hospitalizations for cardiac disease and stroke among the elderly. New England Journal of Medicine, 348(14), 1322–1332.
Nichol, K.L., Nordin, J.D., Nelson, D.B., Mullooly, J.P., Hak, E. (2007). Effectiveness of influenza vaccine in the community-dwelling elderly. New England Journal of Medicine, 357(14), 1373–1381.
Tang, J.W., Ngai, K.L., Wong, J.C., Lam, W.Y., Chan, P.K. (2008). Emergence of adamantane-resistant influenza A(H3N2) viruses in Hong Kong between 1997 and 2006. Journal of Medical Virology, 80(5), 895–901.
Saito, R., Suzuki, Y., Li, D., Zaraket, H., Sato, I., Masaki, H., et al (2008). Increased incidence of adamantane-resistant influenza A(H1N1) and A(H3N2) viruses during the 2006–2007 influenza season in Japan. Journal of Infectious Diseases, 197(4), 630–632; (author reply, 632–633).
Escuret, V., Frobert, E., Bouscambert-Duchamp, M., Sabatier, M., Grog, I., Valette, M., et al (2008). Detection of human influenza A (H1N1) and B strains with reduced sensitivity to neuraminidase inhibitors. Journal of Clinical Virology, 41(1), 25–28.
Smith, N.M., Bresee, J.S., Shay, D.K., Uyeki, T.M., Cox, N.J., Strikas, R.A. (2006). Prevention and Control of Influenza: recommendations of the Advisory Committee on Immunization Practices (ACIP). (Mort Morb Wkly Rep, 55(RR-10), 1–42).
Liu, Y., Wang, H., Chen, M., Sun, Z., Zhao, R., Zhang, L., et al (2008). Serotype distribution and antimicrobial resistance patterns of Streptococcus pneumoniae isolated from children in China younger than 5 years. Diagnostic Microbiology and Infectious Diseases, 61, 256–263.
Middleton, D.B., Zimmerman, R.K., Mitchell, K.B. (2007). Vaccine schedules and procedures, 2007. Journal of Family Practice, 56(2 Suppl. Vaccines), S47–S60; C4–C8.
Chi, R.C., Jackson, L.A., Neuzil, K.M. (2006). Characteristics and outcomes of older adults with community-acquired pneumococcal bacteremia. Journal of the American Geriatrics Society, 54(1), 115–120.
Gable, C.B., Holzer, S.S., Engelhart, L., Friedman, R.B., Smeltz, F., Schroeder, D., et al (1990). Pneumococcal vaccine. Efficacy and associated cost savings. Journal of the American Medical Association, 264(22), 2910–2915.
Simberkoff, M.S., Cross, A.P., Al-Ibrahim, M., Baltch, A.L., Geiseler, P.J., Nadler, J., et al (1986). Efficacy of pneumococcal vaccine in high-risk patients. Results of a Veterans Administration Cooperative Study. New England Journal of Medicine, 315(21), 1318–1327.
Koivula, I., Sten, M., Makela, P.H. (1999). Prognosis after community-acquired pneumonia in the elderly: a population-based 12-year follow-up study. Archives of Internal Medicine, 159(14), 1550–1555.
http://www.jr2.ox.ac.uk/bandolier/band72/b72-4.html/ (Retrieved on April 21, 2008).
Centers for Disease Control and Prevention. Recommended adult immunization schedule – United States, 2009 MMWR 2008; 57(53), Q1–Q4.
Oxman, M.N., Levin, M.J., Johnson, G.R., Schmader, K.E., Straus, S.E., Gelb, L.D., et al (2005). A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. New England Journal of Medicine, 352(22), 2271–2284.
Hornberger, J., Robertus, K. (2006). Cost-effectiveness of a vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. Annals of Internal Medicine, 145(5), 317–325.
Zostiax. (2005). FDA clinical briefing document for Merck and Co.
Pellissier, J.M., Brisson, M., Levin, M.J. (2007). Evaluation of the cost-effectiveness in the United States of a vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. Vaccine, 25(49), 8326–8337.
Potter, J., Stott, D.J., Roberts, M.A., Elder, A.G., O’Donnell, B., Knight, P.V., et al. (1997). Influenza vaccination of health care workers in long-term-care hospitals reduces the mortality of elderly patients. Journal of Infectious Diseases, 175(1), 1–6.
Suggested Reading
Castle, S.C., Uyemura, K., Fulop, T., Makinodan, T. (2007). Host resistance and immune responses in advanced age. Clinics in Geriatric Medicine, 23(3), 463–479.
Targonski, P.V., Jacobson, R.M., Poland, G.A. (2007). Immunosenescence: role and measurement in influenza vaccine response among the elderly. Vaccine, 25(16), 3066–3099.
Zimmerman, R.K., Middleton, D.B., Burns, I.T., Clover, R.D., Kimmel, S.R. (2007). Routine vaccines across the life span, 2007. Journal of Family Practice, 56(2 Suppl. Vaccines), S18–S37; C1–C3.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2009 Humana Press, a part of Springer Science+Business Media, LLC
About this chapter
Cite this chapter
Biedenbender, R., Gravenstein, S. (2009). Vaccinations. In: Norman, D., Yoshikawa, T. (eds) Infectious Disease in the Aging. Infectious Disease. Humana Press. https://doi.org/10.1007/978-1-60327-534-7_27
Download citation
DOI: https://doi.org/10.1007/978-1-60327-534-7_27
Published:
Publisher Name: Humana Press
Print ISBN: 978-1-60327-533-0
Online ISBN: 978-1-60327-534-7
eBook Packages: MedicineMedicine (R0)